Yuetsu Tanaka Selected Research

Tropical Spastic Paraparesis (Tropical Spastic Paraplegia)

12/2019	EOS, an Ikaros family zinc finger transcription factor, interacts with the HTLV-1 oncoprotein Tax and is downregulated in peripheral blood mononuclear cells of HTLV-1-infected individuals, irrespective of clinical statuses.
12/2017	The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis.
4/2016	Absolute quantification of HTLV-1 basic leucine zipper factor (HBZ) protein and its plasma antibody in HTLV-1 infected individuals with different clinical status.
6/2014	Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
4/2014	Tax posttranslational modifications and interaction with calreticulin in MT-2 cells and human peripheral blood mononuclear cells of human T cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients.
5/2013	Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
9/2012	Upregulation of hsa-miR-125b in HTLV-1 asymptomatic carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis patients.
2/2012	Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease.
9/2011	Molecular and clinical effects of betamethasone in human T-cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients.
12/2007	Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuetsu Tanaka Research Topics

Disease

61	T-Cell Leukemia (Leukemia, T Cell) 01/2022 - 05/2002
59	Infections 01/2022 - 03/2002
40	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 05/2022 - 09/2002
37	Neoplasms (Cancer) 05/2022 - 08/2002
13	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 12/2019 - 05/2002
8	Spinal Cord Diseases 12/2017 - 07/2003
7	Carcinogenesis 04/2015 - 01/2003
6	Inflammation (Inflammations) 01/2020 - 03/2011
5	Virus Diseases (Viral Diseases) 03/2009 - 07/2003
4	Lymphoma (Lymphomas) 11/2019 - 03/2005
3	Vesicular Stomatitis 01/2018 - 04/2011
3	HTLV-I Infections (HTLV-I Infection) 02/2016 - 05/2002
3	Acquired Immunodeficiency Syndrome (AIDS) 02/2013 - 03/2004
3	T-Cell Lymphoma (Lymphoma, T Cell) 06/2006 - 01/2003
2	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 05/2013
2	Leukemia 11/2016 - 04/2008
2	Persistent Infection 08/2013 - 02/2013
2	Breast Neoplasms (Breast Cancer) 03/2011 - 09/2007
2	Neoplasm Metastasis (Metastasis) 02/2009 - 09/2007
1	Hematologic Neoplasms (Hematological Malignancy) 05/2022
1	Coinfection 01/2018
1	Multiple Sclerosis 12/2017

Drug/Important Bio-Agent (IBA)

32	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
11	CytokinesIBA 01/2020 - 04/2003
9	LigandsIBA 01/2018 - 05/2002
9	Oncogene Proteins (Oncogene Protein)IBA 02/2016 - 01/2004
8	tax Gene Products (tax Gene Product)IBA 01/2017 - 06/2006
7	AntigensIBA 01/2017 - 04/2002
7	NF-kappa B (NF-kB)IBA 04/2008 - 09/2002
6	Messenger RNA (mRNA)IBA 05/2022 - 01/2003
6	VaccinesIBA 01/2020 - 08/2003
6	Glycoproteins (Glycoprotein)IBA 01/2018 - 08/2008
5	Trans-Activators (Trans-Acting Factor)IBA 01/2022 - 12/2009
5	Monoclonal AntibodiesIBA 02/2016 - 10/2010
5	OX40 LigandIBA 02/2016 - 10/2010
4	EpitopesIBA 01/2020 - 06/2006
4	ChemokinesIBA 01/2020 - 09/2008
4	InterleukinsIBA 12/2014 - 12/2006
4	Antiviral Agents (Antivirals)IBA 06/2014 - 07/2003
3	Interleukin-10 (Interleukin 10)IBA 01/2022 - 02/2015
3	Pharmaceutical PreparationsIBA 01/2020 - 06/2014
3	Peptides (Polypeptides)IBA 01/2018 - 06/2006
3	Transcription Factors (Transcription Factor)IBA 04/2016 - 09/2002
3	Biological ProductsIBA 05/2013 - 11/2007
3	Interleukin-2 (IL2)IBA 09/2005 - 04/2002
2	EnzymesIBA 01/2022 - 04/2016
2	Histones (Histone)IBA 11/2019 - 10/2010
2	ChromatinIBA 11/2019 - 03/2013
2	Cell Adhesion Molecule-1IBA 01/2019 - 01/2016
2	Neutralizing AntibodiesIBA 01/2018 - 03/2011
2	OX40 ReceptorsIBA 01/2018 - 04/2011
2	env Gene ProductsIBA 01/2018 - 11/2007
2	Interleukin-2 Receptors (IL 2 Receptor)IBA 10/2017 - 01/2017
2	Interferon Type IIBA 07/2017 - 04/2017
2	Interleukin-4 (Interleukin 4)IBA 04/2017 - 01/2008
2	MicroRNAs (MicroRNA)IBA 04/2016 - 09/2012
2	AntibodiesIBA 06/2014 - 08/2005
2	(2E,4E,6E,10E)- 3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acidIBA 02/2013 - 03/2006
2	HLA Antigens (Human Leukocyte Antigens)IBA 10/2012 - 05/2005
2	DNA (Deoxyribonucleic Acid)IBA 04/2012 - 09/2008
2	phytobacteriomycin (PBM)IBA 04/2010 - 01/2004
2	RetinoidsIBA 11/2008 - 03/2006
2	Cell Adhesion MoleculesIBA 09/2008 - 08/2002
2	Polysaccharides (Glycans)IBA 11/2007 - 01/2005
2	Histone Deacetylase InhibitorsIBA 12/2006 - 05/2004
2	CurcuminIBA 03/2006 - 02/2006
2	SurvivinIBA 07/2005 - 01/2005
2	3- (4- methylphenylsulfonyl)- 2- propenenitrileIBA 05/2003 - 09/2002
1	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 05/2022
1	Glucose (Dextrose)FDA LinkGeneric 05/2022
1	Adenosine Triphosphate (ATP)IBA 05/2022
1	NADP (NADPH)IBA 05/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2022
1	Sodium-Glucose Transport ProteinsIBA 05/2022
1	ImmunosorbentsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Type II Tumor Necrosis Factor ReceptorsIBA 01/2022
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022
1	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2018
1	Syndecan-1 (Syndecan 1)IBA 01/2018
1	Neuropilin-1IBA 01/2018
1	Liposomes (Liposome)IBA 01/2018
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2018
1	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 01/2018
1	Chemotactic FactorsIBA 12/2017
1	CC ChemokinesIBA 12/2017
1	Minocycline (Cyclops)FDA LinkGeneric 12/2017
1	CalciumIBA 10/2017
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 03/2017
1	Carbonic Anhydrase IXIBA 03/2017
1	Cyclin-Dependent Kinase 9IBA 01/2017
1	Positive Transcriptional Elongation Factor BIBA 01/2017

Therapy/Procedure

9	Therapeutics 08/2018 - 12/2006
7	Immunotherapy 01/2020 - 03/2005
2	Transplantation 02/2015 - 02/2004
2	Ligation 11/2013 - 10/2011
1	Blood Transfusion (Blood Transfusions) 01/2022